Synceres Biosciences Overview
- Year Founded
-
2019
- Status
-
Private
- Latest Deal Type
-
Series A1
- Investors
-
7
Synceres Biosciences General Information
Description
Developer of synthetic biology. The company mainly uses microorganisms as cell factories. With the help of engineering science concepts, through the logical design and directional evolution of gene combination, gene regulation network and signal transduction pathway, providing clients with new functional pathways or new enzymes to produce various active ingredient products.
Contact Information
Website
www.synceres.comCorporate Office
- 402, block B, Nanshan medical device Industrial Park, No. 1019
- Nanhai Avenue, Shekou, Nanshan District
- Shenzhen, Guangdong
- China
Corporate Office
- 402, block B, Nanshan medical device Industrial Park, No. 1019
- Nanhai Avenue, Shekou, Nanshan District
- Shenzhen, Guangdong
- China
Synceres Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A1) | 15-Jun-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 16-Mar-2022 | Completed | Generating Revenue | |||
| 1. Early Stage VC | 21-Feb-2021 | Completed | Generating Revenue |
Synceres Biosciences Patents
Synceres Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025245775-A1 | Separation and purification method for squalene produced by biosynthesis and fermentation | Pending | 30-May-2024 | ||
| WO-2024197449-A1 | Exogenous promoter in saccharomyces cerevisiae and use of exogenous promoter in synthetic biology | Inactive | 24-Mar-2023 | ||
| WO-2024197447-A1 | Hmg-coa reductase mutant and use thereof in production of terpenoids | Inactive | 24-Mar-2023 | ||
| WO-2024113412-A1 | Microbial cell for producing cannabigerol, construction method therefor, and use thereof | Inactive | 03-Dec-2022 | ||
| WO-2024098353-A1 | Recombinant saccharomyces cerevisiae for producing cannabigerolic acid, construction method therefor, and use thereof | Inactive | 11-Nov-2022 |
Synceres Biosciences Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bloomage International | Corporation | Minority | ||
| Co-Stone Capital | PE/Buyout | Minority | ||
| New Value Capital (China) | Venture Capital | Minority | ||
| Shenzhen Chongshi Private Equity Investment Fund Management | PE/Buyout | Minority | ||
| Tasly Holding Group | Corporation | Minority |
Synceres Biosciences FAQs
-
When was Synceres Biosciences founded?
Synceres Biosciences was founded in 2019.
-
Where is Synceres Biosciences headquartered?
Synceres Biosciences is headquartered in Shenzhen, China.
-
What industry is Synceres Biosciences in?
Synceres Biosciences’s primary industry is Drug Discovery.
-
Is Synceres Biosciences a private or public company?
Synceres Biosciences is a Private company.
-
What is Synceres Biosciences’s current revenue?
The current revenue for Synceres Biosciences is .
-
How much funding has Synceres Biosciences raised over time?
Synceres Biosciences has raised $15.8M.
-
Who are Synceres Biosciences’s investors?
Bloomage International, Co-Stone Capital, New Value Capital (China), Shenzhen Chongshi Private Equity Investment Fund Management, and Tasly Holding Group are 5 of 7 investors who have invested in Synceres Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process